Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 2 de 2
Filtre
1.
Chinese Journal of Gastrointestinal Surgery ; (12): 547-551, 2013.
Article Dans Chinois | WPRIM | ID: wpr-357192

Résumé

<p><b>OBJECTIVE</b>To investigate the difference of local immune microenvironment in primary tumors between liver-metastasis and non-liver-metastasis cohort in stage III to IIII colorectal cancer patients.</p><p><b>METHODS</b>Tumor samples from 167 patients of colorectal cancer were harvested, who received tumor resection for the first time in The First Affiliated Hospital of Sun Yat-sen University from 2000 to 2005. Patients were divided into two groups according to liver metastasis or not. Expressions of 18 immune markers, including CD3, CD4 and CD8 were examined and quantified by immunohistochemistry staining.</p><p><b>RESULTS</b>No significant differences of gender, age, BMI, tumor differentiation, pathology type and preoperative CEA level were found between the two groups. The expressions of CD8, CD45RO, IL-17, tryptase and FAS were lower in liver-metastasis group as compared to non-liver-metastasis group (all P<0.05).</p><p><b>CONCLUSIONS</b>Decrease of the number of T lymphocyte and mast cell may play an important role in local infiltration of immune microenvironment of stage III to IIII colorectal cancer with liver metastasis.</p>


Sujets)
Adulte , Sujet âgé , Sujet âgé de 80 ans ou plus , Femelle , Humains , Mâle , Adulte d'âge moyen , Jeune adulte , Marqueurs biologiques tumoraux , Métabolisme , Tumeurs colorectales , Allergie et immunologie , Anatomopathologie , Tumeurs du foie , Allergie et immunologie
2.
Chinese Journal of Cancer ; (12): 184-188, 2010.
Article Dans Anglais | WPRIM | ID: wpr-292613

Résumé

<p><b>BACKGROUND AND OBJECTIVE</b>Male breast cancer (MBC) in China usually has been studied retrospectively with small sample size, and studies analyzing the prognostic factors are rare. This study was to investigate the prognostic factors of Chinese patients with MBC based on the data from a single institute with a relatively large sample.</p><p><b>METHODS</b>Clinical data of 72 patients with histopathologically confirmed MBC who received treatment at Sun Yat-sen University Cancer Center between January 1969 and March 2009, were collected. Kaplan-Meier, log-rank test and Cox regression model were used for statistical analysis.</p><p><b>RESULTS</b>The 5-year overall survival rate was 72.4%, and the survival rates for stage I, II, III, and IV were 100%, 74.2%, 57.2%, and 0%, respectively. Univariate analysis showed that the tumor size (P < 0.001), axillary lymph node status (P = 0.001), TNM stage (P = 0.001), operation model (with vs. without: P < 0.001; classic radical resection vs. modified radical resection, P = 0.336) and endocrine therapy(P = 0.02) significantly influenced the survival. Multivariate Cox regression showed that TNM stage (P = 0.035), operation model (P = 0.021) and endocrine therapy (P = 0.019) were independent prognostic factors for MBC.</p><p><b>CONCLUSIONS</b>Early diagnosis and comprehensive treatment strategy consisting of surgery and endocrine treatment is essential to improve the survival of the patients with MBC, and TNM stage, operation and endocrine treatment are the significant prognostic factors for MBC.</p>


Sujets)
Adulte , Sujet âgé , Sujet âgé de 80 ans ou plus , Humains , Mâle , Adulte d'âge moyen , Antinéoplasiques hormonaux , Utilisations thérapeutiques , Tumeurs osseuses , Tumeur du sein de l'homme , Anatomopathologie , Chirurgie générale , Thérapeutique , Carcinome canalaire du sein , Anatomopathologie , Chirurgie générale , Thérapeutique , Carcinome intracanalaire non infiltrant , Anatomopathologie , Chirurgie générale , Thérapeutique , Carcinome lobulaire , Anatomopathologie , Chirurgie générale , Thérapeutique , Traitement médicamenteux adjuvant , Études de suivi , Métastase lymphatique , Mastectomie , Méthodes , Récidive tumorale locale , Stadification tumorale , Modèles des risques proportionnels , Radiothérapie adjuvante , Études rétrospectives , Taux de survie , Tamoxifène , Utilisations thérapeutiques , Torémifène , Utilisations thérapeutiques , Charge tumorale
SÉLECTION CITATIONS
Détails de la recherche